Danaher shares fell 12.1% this week despite second-quarter earnings beating estimates and management raising full-year EPS guidance to $8.45-$8.60 from $8.35-$8.55. The decline was driven by a reduction in full-year core sales growth expectations for the high-margin biotechnology segment, where consumables sales missed expectations due to a few large chromatography resin shipments moving out of the year. Analysts questioned why the shipments would not simply shift to later quarters, and CEO Rainer Blair confirmed the timing change. The sell-off appears to be an overreaction to an otherwise positive report, presenting a potential buying opportunity for long-term investors.
Danaher CorporationQ2 earnings beat and raised EPS guidance, but sell-off on biotech consumables timing shift is an overreaction.
NVIDIA Corporation